Due to the rapid development of stem cell technology, there have been tremendous
advances in molecular biological and pathological research, cell therapy as well as …

Chronic myelomonocytic leukemia (CMML) is an aggressive disease in which survival after
allogeneic hematopoietic stem cell transplantation (HCT) remains relatively poor. An …

Background The role of cytoreduction prior to hematopoietic cell transplant (HCT) for
patients with pediatric myelodysplastic syndrome (MDS) and related disorders remains …

Background The topic of minimal residual disease (MRD) has emerged as a crucial subject
matter in the domain of oncology in recent years. The detection and monitoring of MRD have …

Simple Summary Myelodysplastic Neoplasms (MDS) are a type of blood cancer presenting
as ineffective production of blood cells, even though the bone marrow appears active …

There is a clear medical need to change the current strategy of “one-size-fits-all”
immunosuppression for controlling transplant rejection to precision medicine and targeted …

Introduction: Donor lymphocyte infusion (DLI) is one of the effective options for post-
transplant disease control of myelodysplastic syndrome (MDS). Its success or failure …

Currently, the post-remission treatment in acute leukemia is based on the genetic profile of
leukemic cells at diagnosis (ie, FLT3 ITD positivity) and on the level of measurable residual …

Introduction: Commonly used scoring systems rely on blood counts, histological and
cytological examination of bone marrow and peripheral blood as well as cytogenetic …

Minimal residual disease, or measurable residual disease (MRD), has emerged as one of
the most important independent prognostic factors in acute leukemia. Extrapolating from …